Switzerland’s Novartis buys US biotech firm Spinifex

29 Jun 2015 | Author: | No comments yet »

Switzerland’s Novartis buys US-based biotech firm Spinifex Pharmaceuticals for undisclosed sum.

BERLIN – Swiss drug manufacturer Novartis says it is buying Spinifex Pharmaceuticals, a U.S.-based biotechnology company that specializes in developing treatments for chronic pain. Novartis didn’t disclose financial details Monday of the agreement to buy privately held Spinifex, which has its headquarters in Stamford, Connecticut, and an office in Melbourne, Australia. The head of Novartis Pharmaceuticals, David Epstein, said that Spinifex’s lead product, EMA401, “could provide a novel, differentiated treatment approach to provide relief for patients and healthcare providers worldwide.”

Here you can write a commentary on the recording "Switzerland’s Novartis buys US biotech firm Spinifex".

* Required fields
Twitter-news
Our partners
Follow us
Contact us
Our contacts

About this site